Author:
Burger David M.,Schwietert H. Reinier,Colbers E. P. H. (Angela),Becker Mark
Subject
Pharmacology (medical),Pharmacology
Reference9 articles.
1. CONVERSION OF THE HIV PROTEASE INHIBITOR NELFINAVIR TO A BIOACTIVE METABOLITE BY HUMAN LIVER CYP2C19
2. 2 JH Lillibridge, CA Lee, YK Pithavala, RG Daniels, TM Samuel, EY Wu, KE Zhang, EL Mazabel, M Zhang, and BM Kerr . The Role of Polymorphic CYP 2C19 in the Metabolism of Nelfinavir Mesylate. 12th AAPS Conference 1998, abstract 3035.
3. Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease
4. Influence of CYP2C19 Pharmacogenetic Polymorphism on Proton Pump Inhibitor-based Therapies
5. Ethnic Differences in Genetic Polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献